Medical device and drugmaker Abbott Laboratories has agreed to pay a $100 million national settlement over the illegal off-label marketing of its anti-seizure drug Depakote. Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder. However, attorneys general in Illinois and 44 other states alleged Abbott Laboratories marketed the drug for unapproved uses, including treatment of schizophrenia, agitated
dementia, and autism. Under the settlement, Illinois-based Abbott also will be restricted from marketing the drug for off-label uses not approved by the Food and Drug Administration. Virginia Attorney General Ken Cuccinelli calls it the largest consumer protection-based pharmaceutical settlement in the nation.
Support Your Public Radio Station